1. Pink Sheet
  2. >>Vaccines

RSV Vaccines: ACIP Recommendations For Adults Younger Than Age 60 Await More Data

 
• By Sue Sutter

GSK’s Arexvy and Pfizer’s Abrysvo are FDA-approved for individuals younger than 60 years old, but CDC’s Advisory Committee on Immunization Practices wants more data on Guillain-Barré syndrome cases in older adults and efficacy in severely immune-compromised persons before making a recommendation.

Delayed
ACIP recommendations on use of RSV vaccines in younger adults are delayed pending more data. (Shutterstock)

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is not ready to make a recommendation on respiratory syncytial virus vaccination for individuals younger than 60, even though two vaccines are now approved for the use.

Currently, all adults ages older than 75, and those ages 60-74 who are at increased risk of severe disease, are recommended to get a single dose of RSV vaccine. However, GSK’s Arexvy and

Key Takeaways
  • The Advisory Committee on Immunization Practices is not making a recommendation for RSV vaccine use in adults younger than 60, even though both Pfizer’s Abrysvo and GSK’s Arexvy are now approved in the age group.
  • ACIP’s adult RSV work group still is weighing data on Guillain-Barre syndrome cases with the two vaccines in older adults and wants clinical efficacy data in immune-compromised populations

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 
• By Sarah Karlin-Smith

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

More from Geography

HHS Negotiating With Manufacturers On Most Favored Nation Drug Pricing

 
• By Cathy Kelly

MFN policy would would apply to all single source drugs in all insurance markets, according to HHS release. Secretary Robert F. Kennedy Jr. said the department is discussing the plan with drug sponsors.

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.